(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 July 2015 (02.07.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/099609 A1

(51) International Patent Classification:
C07K 14/11 (2006.01) *C12N 15/44* (2006.01)
C07H 21/04 (2006.01) *A61K 39/145* (2006.01)
C12N 7/01 (2006.01) *A61P 31/16* (2006.01)

(21) International Application Number:
PCT/SG2014/000594

(22) International Filing Date:
12 December 2014 (12.12.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/920,187 23 December 2013 (23.12.2013) US

(71) Applicant: **TEMASEK LIFE SCIENCES LABORATORY LIMITED** [SG/SG]; National University of Singapore, 1 Research Link, Singapore 117604 (SG).

(72) Inventors: **HE, Fang**; c/o TEMASEK LIFE SCIENCES LABORATORY LIMITED, National University of Singapore, 1 Research Link, Singapore 117604 (SG). **KWANG, Hwei-Sing, Jimmy**; c/o TEMASEK LIFE SCIENCES LABORATORY LIMITED, National University of Singapore, 1 Research Link, Singapore 117604 (SG). **MOOKKAN, Prabakaran**; c/o TEMASEK LIFE SCIENCES LABORATORY LIMITED, National University of Singapore, 1 Research Link, Singapore 117604 (SG).

(74) Agent: **MATTEUCCI, Gianfranco**; Marks & Clerk Singapore LLP, Tanjong Pagar, P O Box 636, Singapore 910816 (SG).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: MONOVALENT H5 VACCINE

Figure 5



(57) Abstract: The present invention relates to a monovalent H5N1 vaccine. More specifically, the present invention relates to the development of a monovalent H5 vaccine strain using hemagglutinin (HA) engineering to elicit cross-clade protection. The present invention also relates to an epitope-chimeric H5 and to a reverse genetics (RG) influenza virus expressing the epitope-chimeric H5.

WO 2015/099609 A1

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*